All In Biotech

Drug Trial Radar · NCT06780826

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

A Simulated RCT Study on the Efficacy of Atezolizumab Combined with Chemotherapy Versus Placebo Combined with Chemotherapy in Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,430

Planned (sponsor's estimate)

Start

Aug 28, 2024

Primary completion

Jun 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter phase III simulated RCT study aimed to compare the efficacy and safety of atezolizumab combined with chemotherapy versus placebo combined with chemotherapy in small cell lung cancer.

Conditions

  • Lung Cancer, Small Cell

Interventions

  • AtezolizumabDrug

    Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle

  • EtoposideDrug

    Etoposide,intravenous infusion, 100mg/m,21 days per cycle

  • CarboplatinDrug

    carboplatin,intravenous infusion, AUC=5, 21 days per cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression free survivalTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.